Lilly Xigris Label Could Exclude Lower-Risk And Sickest Sepsis Patients

Xigris, if approved, should be restricted to those severe sepsis patients defined by exclusion criteria in Lilly's pivotal trial, FDA's Anti-Infective Drug Advisory Committee recommended Oct. 16.